New hormonal therapies for castration-resistant prostate cancer. - Wikidata - awgldk - TriplyDB

New hormonal therapies for castration-resistant prostate cancer.

New hormonal therapies for castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q35196715

about

Insights into Chemoresistance of Prostate Cancer Abiraterone in prostate cancer: a new angle to an old problem The link between androgen receptor splice variants and castration-resistant prostate cancer.Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Androgen receptor antagonists in castration-resistant prostate cancer.Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.Metformin targets c-MYC oncogene to prevent prostate cancer.Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum Targeting cell cycle and hormone receptor pathways in cancer.

P2860

Q26795589-99EDB071-874C-41FC-957B-412DD78185E6 Q26828810-C8DFEB08-1954-4140-B446-5F263001FB80 Q30618562-0D3942DD-55BB-4ACE-A539-BCB75220E9D7 Q33775723-3C0468E4-A7AE-4947-BB45-89953C7145A0 Q34323656-5B7EA2E8-6F8E-4CAC-A12E-CEC1B09DA1B4 Q35603263-4C6ADBB9-C142-42D4-BD62-8F99DFB8257E Q37354564-06EF2B40-FDB1-4C1B-BB7B-C54022F5D439 Q37400228-3E5DF307-D20E-4FF6-9663-B1A426E3B31C Q37502364-1A8D104C-E9CC-49E5-866D-1E84B8FFABD7

P2860

New hormonal therapies for castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q35196715

description

2011 nî lūn-bûn

@nan

2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

New hormonal therapies for castration-resistant prostate cancer.

@ast

New hormonal therapies for castration-resistant prostate cancer.

@en

type

label

New hormonal therapies for castration-resistant prostate cancer.

@ast

New hormonal therapies for castration-resistant prostate cancer.

@en

prefLabel

New hormonal therapies for castration-resistant prostate cancer.

@ast

New hormonal therapies for castration-resistant prostate cancer.

@en

P1433

Q35196715-70BDF705-B38E-474E-A10D-78F4EAF8B31E

P1476

Q35196715-02D0498F-7739-44B0-A51D-A74CABCB2D01

P2093

Q35196715-1AB8D0F1-6DB4-4DA0-9C4D-D322DC4C39A3

Q35196715-A8992EB3-5324-4E6A-B579-A73C97577200

P2860

Q35196715-057E19A5-DFC9-40A0-BC21-8439FE921808

Q35196715-058AF85F-99D3-47E6-B4B5-106242AC2C96

Q35196715-0647281D-3BD6-4F2F-9D20-F57E4913122B

Q35196715-07D0C27A-3EED-4D2B-941A-7F3CBA43BDC8

Q35196715-0D3B61FA-B46D-48F0-B434-29A3C914CF0F

Q35196715-11D27E13-6EEB-437D-A64C-954FC3B5CDB3

Q35196715-11F3DA62-E2E4-492B-BAA6-CD62C328035A

Q35196715-12792122-8482-4914-8ACF-D6EA1B13B8B8

Q35196715-15B17F12-F612-40D9-B2D1-E53B2E3FF337

Q35196715-160D9583-6DA5-4C05-916F-75497DDC3516

P304

Q35196715-61B2A82D-F7C5-4E26-97C3-6C9BE7D24CDC

P31

Q35196715-6F45CB91-8D0C-4C6C-B729-146AD5BE5E55

P356

Q35196715-65226C5A-975E-4466-8C17-E3EE416A0F61

P433

Q35196715-F0F009CC-C0A5-4F67-BE16-54B5E356E07A

P478

Q35196715-920931A4-DC48-4377-891F-F269F5628E11

P577

Q35196715-56F492E4-7525-42B2-9A2E-6BBA1CA38610

P5875

Q35196715-924890F8-4EE0-4007-93B7-C63513BE7903

P698

Q35196715-E0AA00EA-AB74-4C01-BE26-BB68F7D2C5F0

P932

Q35196715-FE4AD647-354A-4EBB-9A8C-2B2812AB8E13

P356

J.ECL.2011.05.013

P1433

Endocrinology and Metabolism Clinics of North America

P1476

New hormonal therapies for castration-resistant prostate cancer.

@en

P2093

Elahe A Mostaghel

http://www.w3.org/2001/XMLSchema#string

Stephen Plymate

http://www.w3.org/2001/XMLSchema#string

P2860

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Molecular determinants of resistance to antiandrogen therapy

Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

HE3235 inhibits growth of castration-resistant prostate cancer.

P304

625-42, x

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.ECL.2011.05.013

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2011-07-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51617021

http://www.w3.org/2001/XMLSchema#string

P698

21889725

http://www.w3.org/2001/XMLSchema#string

P932

3167094

http://www.w3.org/2001/XMLSchema#string